NovaBay Pharmaceuticals, Inc.
NBY
$0.6148
$0.01482.47%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 132.94% | 25.07% | 26.34% | 11.99% | 9.16% |
| Total Depreciation and Amortization | -3.42% | 30.62% | 21.09% | 13.97% | 17.07% |
| Total Amortization of Deferred Charges | -76.96% | -48.28% | 28.87% | 328.67% | -- |
| Total Other Non-Cash Items | -82.63% | -42.50% | -34.05% | -1.62% | 0.06% |
| Change in Net Operating Assets | 387.76% | 10.85% | -156.42% | 337.32% | -140.93% |
| Cash from Operations | 264.41% | 6.80% | 17.19% | 61.18% | 39.90% |
| Capital Expenditure | 50.00% | 68.42% | 43.75% | 91.58% | 92.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 50.00% | 68.42% | 43.75% | 91.58% | 92.08% |
| Total Debt Issued | -83.33% | -83.33% | -100.00% | -100.00% | -- |
| Total Debt Repaid | 6.48% | -35.01% | -249.87% | -1,185.49% | -- |
| Issuance of Common Stock | 558.23% | 449.56% | -- | -53.55% | -66.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -855.50% | 36.46% | 99.32% | 99.32% | -- |
| Cash from Financing | -70.37% | -21.47% | -80.41% | -123.33% | -72.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -57.58% | -57.58% | 301.37% | 2,056.25% | -- |
| Net Change in Cash | 412.12% | -10.34% | -614.52% | -588.96% | -35.52% |